Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Actavia Life Sciences Inc (PK) | RASP | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.0169 | 08:30:23 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.0169 | 0.0169 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.0062 - 0.039 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.0169 | USD |
Actavia Life Sciences Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 13.04M | 771.81M | 37.00M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Actavia Life Sciences (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/20/2024 | 11:09 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/15/2024 | 11:59 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 2/16/2024 | 14:47 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2/14/2024 | 14:01 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 1/05/2024 | 09:49 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
| 12/29/2023 | 15:05 | Edgar (US Regulatory) | Form NT 10-K - Notification of inability to timely file Form.. |
| 8/14/2023 | 07:12 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RASP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.01255 | 0.039 | 0.01255 | 0.0144824 | 30,350 | 0.00435 | 34.66% |
| 1 Month | 0.0173 | 0.039 | 0.011 | 0.014443 | 12,410 | -0.0004 | -2.31% |
| 3 Months | 0.008 | 0.039 | 0.0078 | 0.0131497 | 12,841 | 0.0089 | 111.25% |
| 6 Months | 0.0077 | 0.039 | 0.0077 | 0.0128815 | 7,412 | 0.0092 | 119.48% |
| 1 Year | 0.0062 | 0.039 | 0.0062 | 0.0157474 | 9,302 | 0.0107 | 172.58% |
| 3 Years | 0.0501 | 0.135 | 0.0001 | 0.0264674 | 13,877 | -0.0332 | -66.27% |
| 5 Years | 0.06 | 0.33 | 0.0001 | 0.0484472 | 31,382 | -0.0431 | -71.83% |
Actavia Life Sciences (PK) Description
| Rasna Therapeutics, Inc. (OTC:RASP), a development stage biotechnology company focused on the development of cancer drugs, today announced the successful completion of its merger. Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia (AML), leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna's focus on inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD1 regulators that have shown appropriate effects on the LSD1 gene in-vitro and in IND-enabling pre-clinical studies. |
